Melbourne, Dec 23, 2010 (ABN Newswire) - Benitec Limited (
ASX:BLT) (PINK:BNIKF) is pleased to advise that it will receive a dividend of US$161,674 from its licensee, the California-based biotechnology company, Tacere Therapeutics, Inc. ("Tacere").
The dividend relates to Benitec's equity stake in Tacere and the dividend amount represents US$7.06 per outstanding share of Tacere Common Stock.
As previously announced, Benitec has licensed its gene silencing technology (DNA-directed RNAi) for treating Hepatitis C to Tacere and as consideration, Tacere agreed to upfront and milestone payments and future royalties. The equity stake owned by Benitec in Tacere is part of the overall consideration for the licence agreement between the parties.
Tacere are currently working with Pfizer (NYSE:PFE) to further develop and commercialise Tacere's Hepatitis C Virus compounds.
Dr Peter French, Benitec CEO, said that he was very pleased with the dividend payment, as "...it indicates the potential for significant income as Benitec's technology moves through the commercialization process. Clearly the potential is for this and other projects to yield significant value for shareholders in the future."
ASX:BLT) (PINK:BNIKF) is pleased to advise that it will receive a dividend of US$161,674 from its licensee, the California-based biotechnology company, Tacere Therapeutics, Inc. ("Tacere").The dividend relates to Benitec's equity stake in Tacere and the dividend amount represents US$7.06 per outstanding share of Tacere Common Stock.
As previously announced, Benitec has licensed its gene silencing technology (DNA-directed RNAi) for treating Hepatitis C to Tacere and as consideration, Tacere agreed to upfront and milestone payments and future royalties. The equity stake owned by Benitec in Tacere is part of the overall consideration for the licence agreement between the parties.
Tacere are currently working with Pfizer (
NYSE:PFE) to further develop and commercialise Tacere's Hepatitis C Virus compounds.Dr Peter French, Benitec CEO, said that he was very pleased with the dividend payment, as "...it indicates the potential for significant income as Benitec's technology moves through the commercialization process. Clearly the potential is for this and other projects to yield significant value for shareholders in the future."
| Tweet |
About Benitec Limited
Benitec Limited (ASX:BLT) (PINK:BNIKF) holds a dominant position in expressed RNA interference (RNAi)-based human therapeutics, with a transformational platform technology supported by a robust and extensive intellectual property portfolio. Benitec is leveraging this platform to develop and build a pipeline of expressed RNAi therapeutics focusing on treatment and alleviation of cancer and infectious disease. With strong global partnerships and committed scientific and clinical investigators, Benitec Ltd aims to deliver a range of novel RNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry.
|
||
|
 |
Related Companies |
>>>       Benitec Limited>>>    Pfizer Inc. |
| |
Related Industry Topics: |
Biotech | Drugs & OTC | Financial General | Health & Pharm General | |
| |
This Page Viewed: (Last 7 Days: 130) (Last 30 Days: 570) (Since Published: 17760) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
|
Pfizer Inc. | ||||||
|
|||||||
Companies in the News
Mobile Video TV
|
||
|
||
){kind=link}